Antigenics’ Oncophage Approved In Russia, First Therapeutic Cancer Vaccine To Enter Marketplace
This article was originally published in The Pink Sheet Daily
Executive Summary
The biologic will launch this summer at a price in the lower range of $50,000-$100,000/patient/year, the typical cost of new cancer drugs in Russia, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Agenus Teams Up With NewVac On Russian Deal
The Massachusetts biotech has found a partner to commercialize its cancer vaccine in Russia and develop the drug for other indications.
Antigenics Pulls Oncophage Application Following CHMP Negative Opinion
A month after it learned that Europe's Committee for Medicinal Products for Human Use would hand down a negative opinion on approval on Oncophage (vitespen), Antigenics withdrew its Marketing Application Authorization for the cancer vaccine on Nov. 20
Antigenics Pulls Oncophage Application Following CHMP Negative Opinion
A month after it learned that Europe's Committee for Medicinal Products for Human Use would hand down a negative opinion on approval on Oncophage (vitespen), Antigenics withdrew its Marketing Application Authorization for the cancer vaccine on Nov. 20